Industry Projects ยท Global Strategy & Health-Economic Modelling
Qiyang Medical Research continuously delivers strategy modelling grounded in public market data and health-economic models โ a "data-driven, model-validated" reference for going-overseas decisions, not just expert judgment.
Research themes
We model the common strategic questions Chinese healthcare companies face when going overseas โ spanning pharmaceuticals, medical devices and emerging medical technology.
Licensing vs NewCo vs Direct Overseas Expansion
Quantitatively compares architectures โ pure licensing, NewCo "borrowing-a-boat" expansion, direct overseas entry, phased hybrids โ for expected returns and retained value over a 10-year and a longer horizon, identifying "who controls commercialization rights" as the crux of the value gap.
Global commercialization strategy modelling for innovative drugs
Using an "icebreaker + fleet" model of global commercialization, measures the long-term value difference between direct overseas expansion and license-out, and evaluates how brand, channel and pricing power reshape the revenue curve.
Global footprint for metabolic disease (GLP-1)
For the diabetes / GLP-1 space, models the global patient pool, market growth, and the cumulative revenue and compounding advantages of a phased three-stage hybrid model โ supporting enterprises in choosing a staged overseas path.
Medical technology & AI devices going global
Covers emerging fields such as AI medical imaging (SaMD) and eldercare robots โ from product-attribute determination and target-country regulation (e.g., Saudi SFDA) to strategy modelling for globally scalable markets.
Health-economic evaluation of eldercare monitoring technology
Health-economic evaluation of eldercare technologies such as millimetre-wave contactless monitoring: cost-effectiveness, budget-impact and health-outcome modelling โ an evidence base for deploying technology in care settings.
Methodology
๐ Public-data foundation
Built on company disclosures and authoritative industry and epidemiological data (WHO / IDF, etc.), keeping every model traceable and reproducible.
๐งฎ Health-economic modelling
Probability-weighted decision analysis, Markov / three-stage hybrid models, sensitivity analysis and scenario reasoning โ producing expected-value ranges rather than a single number.
๐งญ Decision-oriented
Translates complex models into executable strategic recommendations โ which overseas architecture to choose, when to license, when to go direct, and how to price.
Disclaimer: The above research is modelled on public market data and health-economic models. All projections are probability-weighted expected values provided for strategic reference only and do not constitute investment advice. Actual results may differ materially due to changes in market structure, policy and competition.
Representative project ยท AI medical imaging (SaMD) entry into Saudi Arabia
Commissioned by a Chengdu-based medical company, we completed a strategic brief for its AI medical imaging product entering the Saudi market โ assessing six decisions: product-attribute determination โ overseas qualification โ charging model โ market footprint โ timeline โ globally scalable markets. (This case is presented with the partner's authorization; name withheld at the partner's request.)
๐ฌ Saudi regulatory determination
Software whose imaging results are used for disease diagnosis, screening, monitoring or decision support qualifies as medical-device software (SaMD) and must obtain Saudi SFDA marketing authorization (MDMA). The SFDA does not accept foreign approvals, so a full technical file assessment (TFA) is required.
๐ Overseas qualification pathway
First secure approval in a GHTF member country (EU/US/CA/JP/AU) as a prerequisite for the TFA; meet ISO 13485 (Saudi version), the data-governance and cybersecurity requirements for AI products (MDS-G series), and appoint a Saudi Authorized Representative (AR).
๐๏ธ Implementation & charging structure
No local Saudi entity is required; we recommend an independent licensed AR to avoid being "registration-locked" by a distributor. Data is stored locally in line with Saudi regulations, and delivery uses a "registration package + market services" structure.
๐ Global scalability
Combining Chinese NMPA approval with overseas mutual-recognition pathways, assesses the priority order and pacing for replicating and scaling from Saudi Arabia into the GCC and other emerging markets.
Note: This case presents only the methodology and access-pathway framework and does not include the partner's undisclosed delivery details. Actual registration timelines and market costs vary by product and submission scope and are subject to a formal commercial assessment.
Ongoing academic research
Qiyang Medical Research's team pursues ongoing academic research in health economics and outcomes research (HEOR) and health technology assessment (HTA), building methodological depth on global licensing strategy, market access and long-term value creation for Chinese innovative drugs and devices โ and sharing findings through papers and industry reports.
Research strengths: probability-weighted decision analysis ยท long-term value modelling of licensing vs direct overseas entry ยท payer access and cost-effectiveness (CEA / BIA) ยท globalization strategy for Chinese healthcare companies.
Need a strategy model run for your product?
Qiyang Medical Research can tailor an overseas-architecture comparison and global footprint model for you.
Request custom research